The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.
Peter J. Goebell
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
Ulrich Kube
No relevant relationships to disclose
Michael Staehler
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Christian Doehn
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Thomas Steiner
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Manfred Kindler
No relevant relationships to disclose
Edwin Herrmann
No relevant relationships to disclose
Jan Janssen
No relevant relationships to disclose
Steffen Weikert
Consultant or Advisory Role - Bayer; Genentech; MOLOGEN; Novartis; Pfizer
Other Remuneration - Bayer; GlaxoSmithKline; Novartis; Pfizer
Michael Thomas Scheffler
No relevant relationships to disclose
Joerg Schmitz
No relevant relationships to disclose
Friedrich Overkamp
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis
Michael Albrecht
Employment or Leadership Position - Novartis
Lothar Bergmann
Consultant or Advisory Role - Novartis
Honoraria - Novartis